A high-affinity subtype-selective fluorescent probe for estrogen receptor β imaging in living cells.

A high-affinity subtype-selective fluorescent probe for estrogen receptor β imaging in living cells. Chem Commun (Camb). 2018 Apr 03;: Authors: Hu Z, Yang L, Ning W, Tang C, Meng Q, Zheng J, Dong C, Zhou HB Abstract Estrogen receptor β (ERβ) has recently been identified as a pharmaceutical target in hormone replacement therapy for breast cancers. However, the biological function of ERβ in disease progression remains unclear. A highly ERβ-selective fluorescent probe (FPNM) was discovered exhibiting nanomolar affinity for ERβ with an ERβ/ERα selectivity as high as 80, which allowed specific labeling of intracellular ERβ. Moreover, distinct ERβ dynamics in various cellular bio-settings such as prostate cancer (DU-145) or triple-negative breast cancer (MDA-MB-231) cells were directly observed for the first time via FPNM staining. PMID: 29610818 [PubMed - as supplied by publisher]
Source: Chemical Communications - Category: Chemistry Authors: Tags: Chem Commun (Camb) Source Type: research

Related Links:

From time to time I have commented on the controversies over cancer screening. Most people assume that screening is an unqualified good, that early detection of cancer saves lives. Whenever some panel proposes recommending less screening, we hear screaming and yelling from advocates who claim they are trying to " ration " health care to save money at the expense of people's lives.In fact,as a bunch of Australians and a Minnesotan explain in BMJ, there are a few conditions called " cancer " that you are better off not treating, or perhaps treating very conservatively. These include what is called ductal ...
Source: Stayin' Alive - Category: American Health Source Type: blogs
(University of East Anglia) A new cancer therapy using nanoparticles to deliver a combination therapy direct to cancer cells could be on the horizon.Using nanoparticles to get drugs directly into a tumor is a growing area of cancer research. The technology developed at UEA is the first of its kind to use nanoparticles to deliver two drugs in combination to target cancer cells. The therapy has been shown to make breast cancer and prostate cancer tumors more sensitive to chemotherapy.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Publication date: September 2018Source: Diabetes &Metabolic Syndrome: Clinical Research &Reviews, Volume 12, Issue 5Author(s): Natalia V. Yunusova, Irina V. Kondakova, Larisa A. Kolomiets, Sergey G. Afanas’ev, Anastasia Yu. Kishkina, Liudmila V. SpirinaAbstractMetabolic syndrome (MS) is one of the leading risk factors for the development of some common cancers (endometrial cancer, postmenopausal breast cancer, colorectal cancer). Currently, a drug-induced metabolic syndrome related with androgen deprivation therapy in patients with prostate cancer represents a serious medical problem. Not only MS, or its indi...
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
CONCLUSIONS: Our study found that men with a family history of breast or prostate cancer had elevated prostate cancer risks, including risk of lethal disease. These findings have translational relevance for cancer risk prediction in men. PMID: 30082473 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
×. Güniz Küçükgüzel Cyclooxygenase enzymes play a vital role in inflammatory pathways in the human body. Apart from their relation with inflammation, the additional involvement of COX-2 enzyme with cancer activity was recently discovered. In some cancer types the level of COX-2 enzyme is increased indicating that this enzyme could be a suitable target for cancer therapy. Based on these findings, we have synthesized some new diflunisal thiosemicarbazides and 1,2,4-triazoles and tested them against androgen-independent prostate adenocarcinoma (PC-3), colon carcinoma (HCT-116), human breast canc...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Purpose of review Poly (ADP-ribose) polymerase inhibitors (PARPi) are approved drugs for the treatment of ovarian and breast cancer and currently under investigation for the treatment of prostate cancer and other malignancies with aberrations in homologous recombination DNA repair. This review summarizes literature published during 2017 concerning the relevance of PARPi in prostate cancer and presents new evidence on mechanisms of resistance and biomarkers of response. Recent findings The approval of several PARPi (olaparib, rucaparib, and niraparib) has driven the focus of anticancer treatment on synthetic lethality...
Source: Current Opinion in Supportive and Palliative Care - Category: Palliative Care Tags: RENAL AND UROLOGICAL PROBLEMS: Edited by Fred Saad Source Type: research
With a new artificial intelligence (AI) algorithm, planning for radiation therapy...Read more on AuntMinnie.comRelated Reading: Can AI best quantitative MRI in prostate lesions? Breast cancer follow-up imaging varies widely SNMMI: Early prostate cancer therapy extends lives SNMMI: Fluciclovine-PET changes prostate treatment SNMMI: New therapy aids patients with neuroendocrine tumors
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Overdiagnosis is recognized as a major harm of mammography screening for breast cancer and prostate cancer screening with prostate-specific-antigen (PSA). Colorectal cancer screening is being more broadly implemented in many countries, and screening rates are increasing steadily. Surprisingly, there is a striking and almost complete lack of knowledge about overdiagnosis in colorectal cancer screening. Overdiagnosis is not part of patient information material, hardly mentioned in guidelines, and not addressed in scientific or public debate.
Source: Gastroenterology - Category: Gastroenterology Authors: Source Type: research
Abstract The management of bone lesions from advanced solid tumors and multiple myeloma typically includes use of a bone-modifying agent to reduce the risk of skeletal-related events. Recent data demonstrate that when using zoledronic acid to reduce the risk of skeletal-related events in metastatic breast cancer, metastatic prostate cancer, and multiple myeloma, the dosing interval of zoledronic acid may be extended from every 4 weeks to every 12 weeks. The ASCO guidelines on the role of bone-modifying agents in metastatic breast cancer and multiple myeloma address zoledronic acid dosing intervals. Herein, we disc...
Source: JOP - Category: Gastroenterology Authors: Tags: J Oncol Pract Source Type: research
Overdiagnosis is recognized as a major harm of mammography screening for breast cancer and prostate cancer screening with prostate-specific antigen (PSA). Colorectal cancer (CRC) screening is being more broadly implemented in many countries, and screening rates are increasing steadily. Surprisingly, there is a striking and almost complete lack of knowledge about overdiagnosis in CRC screening. Overdiagnosis is not part of patient information material, hardly mentioned in guidelines, and not addressed in scientific or public debate.
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Commentary Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemistry | Hormone Replacement Therapy | Hormones | Men | Nanotechnology | Prostate Cancer